Extraskeletal mesenchymal chondrosarcoma: an imaging review of ten new patients

Hashimoto, Nobuyuki; Ueda, Takafumi; Joyama, Susumu; Araki, Nobuhito; Beppu, Yasuo; Tatezaki, Shin-ichiro; Matsumoto, Seiichi; Nakanishi, K.; Tomita, Yoshihiro; Yoshikawa, Hideki

doi:10.1007/s00256-005-0025-9

Cited by 45 publications

(42 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Few studies have analyzed survival by skeletal and extraskeletal locations. In an analysis of 13 patients with extraskeletal tumors, Hashimoto et al found a 42.8% survival rate at 10 years [11], yet in a separate analysis of 26 tumors, Cesari et al [2] suggested mesenchymal chondrosarcoma of the soft tissues may be a more aggressive disease than its skeletal counterpart with a 10-year survival rate of 0% in such tumors compared with 29% for skeletal tumors. Although the current investigation found extraskeletal tumors to be more common than previously reported, we found no difference in survival between skeletal and extraskeletal tumors.…”

Section: Discussionmentioning

confidence: 99%

“…In comparison to conventional chondrosarcoma, which has a 10-year overall survival rate of 60% to 70% [6,7,9], the mesenchymal subtype is believed to portend a worse prognosis [2,14,17]. The 10-year survivorship of mesenchymal chondrosarcoma has been previously reported as ranging from 20% to 67% [3,8,11,14,15,17,18,21] with cohorts comprised of head and neck tumors or of pediatric patients representing the upper end of this spectrum [4,16,23]. The disease recently was reported to have a median event-free survival of 57 months [25].…”

Section: Introductionmentioning

confidence: 99%

“…Tumor grade, extent of surgical margins, and the presence of distant disease have all been associated with worse outcomes in conventional chondrosarcoma [9]. However, analysis of the effects of these variables on the prognosis of mesenchymal chondrosarcoma has been limited, and differences in survival between skeletal and extraskeletal mesenchymal chondrosarcoma have not been well defined [2,8,11]. Identification of the prognostic implications of disease location has not been completed.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database

Schneiderman

Kliethermes

Nystrom

2017

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Background Studies suggest that mesenchymal chondrosarcoma is associated with a poorer prognosis and a higher proportion of extraskeletal tumors than conventional chondrosarcoma. However, these investigations have been small heterogeneous cohorts, limiting analysis of prognostic factors. Questions/purposes (1) What is the 5-and 10-year survival rate of patients diagnosed with mesenchymal chondrosarcoma? (2) What is the effect of demographic and tumor characteristics on survival in patients with mesenchymal chondrosarcoma? Methods The Surveillance, Epidemiology, and End Results (SEER) database was used to identify all patients diagnosed with mesenchymal chondrosarcoma from 1973 to 2011. SEER reports survival data on over 8.2 million patients with cancer and has attained 98% completeness in reporting. Using variables within the database, this study designated each patient's tumor as skeletal or extraskeletal and cranial, axial, or appendicular, respectively. Overall survival (OS) was determined for the entire series as well as each group. Median survival was calculated using KaplanMeier methods. Cox proportional hazards regression was used to determine whether demographic and tumor variables affected survival. Two hundred five patients with mesenchymal chondrosarcoma were identified, including 82 (40%) skeletal and 123 (60%) extraskeletal. Results OS for the entire series was 51% (95% confidence interval [CI], 43%-58%) and 43% (95% CI, 35%-51%) at 5 and 10 years, respectively. No difference in OS was detected between extraskeletal and skeletal tumors. KaplanMeier analyses showed OS was worse for tumors in axial locations compared with appendicular and cranial locations. Appendicular tumors demonstrated an OS of 50% (95% CI, 36%-63%) at 5 years and 39% (95% CI, 26%-52%) at 10 years. OS for axial tumors was 37% (95% CI, 25%-49%) and 31% (95% CI, 20%-43%), whereas it was 74% (95% CI, 59%-84%) and 67% (95% CI, 50%-79%) for cranial tumors at 5 and 10 years, respectively. When controlling for age, sex, tumor origin, and tumor location, the presence of metastasis (hazard ratio [HR], 12.38; 95% CI, 5.75-26.65; p \ 0.001) and 1-cm size increase (HR, 1.16; 95% CI, 1.09-1.23; p \ 0.001) were both independently associated with an increased risk of death. Tumor location showed different behaviors depending on patient age. In comparison to cranial tumors at age 20 years, the HR was 5.56 (95% CI, 1.47-21.05; p = 0.01) for axial tumors and 6.26 (95% CI, 1.54-25.42; p = 0.01) for appendicular tumors. At age 60 years, those ratios were 0.10 (95% CI, 0.02-0.55; p = 0.01) and 0.14 (95% CI, 0.04-0.58; p = 0.01), respectively. Conclusions Our data suggest that extraskeletal tumors are more common than previously reported; however, this factor does not have clear prognostic value. Presence of metastatic disease and increased tumor size are the main Each author certifies that he or she, or a member of his or her immediate family, has no funding or commercial associations (eg, consultancies, stock ownership, equity interest, paten...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database

Schneiderman

Kliethermes

Nystrom

2017

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

show abstract

“…The gadolinium enhancement pattern of EMC was very rarely reported. Inhomogeneous enhancement pattern and contrast enhancement except low signal intensity areas on T1 weighted MRI were previously described 3,4 . So far to the best of our knowledge the dynamic enhancement pattern of EMC have not been reported previously.…”

Section: Discussionmentioning

confidence: 99%

“…The largest studies evaluating imaging features of EMC were reported by Hashimato et al in 10 patients and Shapero et al in 7 patients 3,4 . To the best of our knowledge we did not recognize any report of MRI with dynamic contrast-enhanced MRI so far.…”

Section: Introductionmentioning

confidence: 99%

El bileğinde ekstraskeletal mezenkimal kondrosarkomun manyetik rezonans görüntüleme bulguları: olgu sunumu

Pourbagher¹,

Aslan²,

Bal³

2016

Cukurova Med J

View full text Add to dashboard Cite

AbstractÖz Extraskeletal mesenchymal chondrosarcomas (EMC) are high grade malignant tumors that rarely involves wrist. Published reports about them are mostly based on conventional radiography, tomography and conventional magnetic resonance imaging (MRI) findings. We did not recognize any report of dynamic-contrast enhanced MRI so far. Herein, we present dynamic contrast enhanced and Diffusion Weighted MRI findings of a case with extraskeletal mesenchymal chondrosarcoma of the wrist.In conclusion, EMC might show peripheral enhancement at early arterial phase and restricted diffusion on MRI. The knowledge of the imaging spectrum of the EMC might help us suggesting the diagnosis.Ekstraskeletal mezenkimal kondrosarkomlar (EMK) el bileğini nadiren tutan yüksek gradeli malign tümörlerdir. Literatürde bildirilen yayınlarda çoğunlukla direk grafi, bilgisayarlı tomografi ve konvansiyonel manyetik rezonans görüntüleme (MRG) bulguları esas alınmıştır. Şimdiye kadar literatürde dinamik kontrastlı MRG bulgularını bildiren yayın bulunmamaktadır. Bu olgu sunumunda EMK' un dinamik kontrastlı ve difüzyon ağırlıklı MRG bulgularını sunduk. Sonuç olarak EMK MRG'de erken arteriyel fazda periferal kontrastlanma ve difüzyon kısıtlaması gösterebilir. EMK'nın görüntüleme bulgularının bilinmesi tanının akla gelmesinde önemlidir.

show abstract

Retroperitoneal mesenchymal chondrosarcoma with metastasis to iliac vein: A rare case report and review of the literature

Esfahani

Mirazimi

Azadbakht

et al. 2022

Clinical Case Reports

View full text Add to dashboard Cite

The iliac vein is an extremely rare site of metastasis for extraskeletal mesenchymal chondrosarcoma (ESMC). Involvement of the veins usually leads to an extremely dismal prognosis. Here, we report a 50-year-old patient with retroperitoneal mesenchymal chondrosarcoma and initial metastasis to the iliac bone, which further progressed to involve the iliac vein. In this study, we reviewed the major characteristics of ESMC and the previously reported cases, considering the rarity of these tumors.

show abstract

Extraskeletal mesenchymal chondrosarcoma: an imaging review of ten new patients

Cited by 45 publications

References 13 publications

Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database

Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database

El bileğinde ekstraskeletal mezenkimal kondrosarkomun manyetik rezonans görüntüleme bulguları: olgu sunumu

Retroperitoneal mesenchymal chondrosarcoma with metastasis to iliac vein: A rare case report and review of the literature

Contact Info

Product

Resources

About